首页 / 院系成果 / 成果详情页

Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir/rilpivirine 期刊论文

编号：

F0537B29A31566B1C360F2B0D300E16E
作者：

Alagaratnam, Jasmini^[1,2];Kelly, Niall^[2];Dustan, Simon^[2];Naous, Nadia^[1];Nwanbila, Modest^[1];Byrne, Ruth^[1];Girometti, Nicolo^[1]Asboe, David^[1];Taylor, Graham P.^[2,3]Boffito, Marta^[1,2];
语种：

英文
期刊：

AIDS ISSN：0269-9370 2025 年 39 卷 1 期 (95 - 98) ; JAN 1
疾病分类：

艾滋病
摘要：

Increasingly, people attending HIV services are requesting long-acting injectable (LAI) antiretroviral treatment (ART). However, without HIV RNA resistance-associated mutation results, individuals are considered unsuitable for LAI ART. We present our experience of sequencing proviral HIV DNA in 30 individuals to inform suitability for LAI ART, of whom 23 were considered suitable. In conclusion, optimization of diagnostic tools such as proviral HIV DNA sequencing to confirm suitability for LAI ART would be a welcome addition.
推荐引用方式
GB/T 7714：

Alagaratnam Jasmini,Kelly Niall,Dustan Simon, et al. Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir/rilpivirine [J].AIDS,2025,39(1):95-98.
APA：

Alagaratnam Jasmini,Kelly Niall,Dustan Simon,Naous Nadia,&Boffito Marta.(2025).Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir/rilpivirine .AIDS,39(1):95-98.
MLA：

Alagaratnam Jasmini, et al. "Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir/rilpivirine" .AIDS 39,1(2025):95-98.
数据来源自科睿唯安Web of Science核心合集
入库时间：

2025/1/3 17:56:19
更新时间：

2025/1/3 17:56:19

浏览次数：7  下载次数：0

分享到：

浏览次数：7

下载次数：0

打印次数：0